A recent incident at a Swiss vitamin B3 production facility has raised questions about potential supply disruptions. While the market has not yet reacted significantly, the event adds uncertainty to an already cautious sector. (Update week 22) Highlights: Vitamin E 50%: The market remains weak with continued force majeure from BASF and sufficient supply from alternative producers. Prices have declined slightly.
Vitamin A 1000: BASF has not resumed production as planned for April 2025. Pri
Get full access to all stories on All About Feed
This Premium article is exclusively available for subscribers.
Obtain insights from exclusive interviews
Dive into articles covering trending industry topics
Stay up-to-date on the market trends
All the news is brought to you by experienced editors and experts from around the world
Marieke
Ploegmakers
Matthew
Wedzerai
Treena
Hein
